Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Digital medicine system (DMS) is a novel drug-device combination that objectively measures and reports medication ingestion. The DMS consists of medication embedded with an ingestible sensor (digital medicine), a wearable sensor, and software applications. This study evaluated usability of the DMS in adults with schizophrenia rated by both patients and their health care providers (HCPs) during 8-week treatment with prescribed doses of digital aripiprazole. METHODS: Six US sites enrolled outpatients into this Phase IIa, open-label study (NCT02219009). The study comprised a screening phase, a training phase (three weekly site visits), and a 5-week independent phase. Patients and HCPs independently rated usability of and satisfaction with the DMS. RESULTS: Sixty-seven patients were enrolled, and 49 (73.1%) patients completed the study. The mean age (SD) of the patients was 46.6 years (9.7 years); the majority of them were male (74.6%), black (76.1%), and rated mildly ill on the Clinical Global Impression - Severity scale (70.1%). By the end of week 8 or early termination, 82.1% (55/67) of patients had replaced the wearable sensor independently or with minimal assistance, based on HCP rating. The patients used the wearable sensor for a mean (SD) of 70.7% (24.7%) and a median of 77.8% of their time in the trial. The patients contacted a call center most frequently at week 1. At the last visit, 78% (47/60) of patients were somewhat satisfied/satisfied/extremely satisfied with the DMS. CONCLUSION: A high proportion of patients with schizophrenia were able to use the DMS and reported satisfaction with the DMS. These data support the potential utility of the DMS in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 2×
“Suicidality was monitored throughout the study using the Columbia-Suicide Severity Rating Scale.”
Fett, A.-K. J., Viechtbauer, W., Dominguez, M.-D.-G., Penn, D. L., van Os, J., & Krabbendam, L. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.07.001 · Cited by 1,833
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Sendt, K.-V., Tracy, D. K., & Bhattacharyya, S. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.002 · Cited by 245
Cognitive impairment in bipolar disorder and schizophrenia: a systematic review
Vöhringer, P. A., Barroilhet, S. A., Amerio, A., Reale, M. L., Alvear, K., Vergne, D., & Ghaemi, S. N. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00087 · Cited by 165
Kane, J. M., Perlis, R. H., DiCarlo, L. A., Au-Yeung, K., Duong, J., & Petrides, G. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08222 · Cited by 81 · cited 1×
“A novel digital medicine system (DMS) has been developed for patients with serious mental illness to objectively measure and report ingestion of aripiprazole, an atypical antipsychotic.(15) Aripiprazole is indicated in adults for the”
Cited by
Batra, S., Baker, R., Wang, T., Forma, F., DiBiasi, F., & Peters-Strickland, T. (2017) · Medical Devices: Evidence and Research · doi:10.2147/mder.s144158 · Cited by 169
Self-citationPresent and Future of Digital Health in Diabetes and Metabolic Disease
Rhee, S. Y., Kim, C., Shin, D. W., & Steinhubl, S. R. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0088 · Cited by 47
The pharmacological treatment of schizophrenia: how far have we come?
Rubio, J. M., & Kane, J. M. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.13 · Cited by 13
“Although several options, including a medication event monitoring system (MEMS), tablets that can register when they are ingested, 72 or digital applications that can document when a pill is ingested, 73 the most reliable and scalable option to address nonadherence is use of an LAI antipsychotic.”
Background
Metadata
- Authors
- Peters-Strickland, T., Pestreich, L., Hatch, A., Rohatagi, S., Baker, R. A., Docherty, J., Markovtsova, L., Raja, P., Weiden, P. J., & Walling, D. P.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2016-10
- Volume
- Volume 12
- Pages
- 2587-2594
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W2530798142
- Cited by
- 72
- References
- 8
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. https://app.cochat.ai/papers/10.2147/ndt.s116029
- The paper
- Peters-Strickland, T., Pestreich, L., Hatch, A., Rohatagi, S., Baker, R. A., Docherty, J., Markovtsova, L., Raja, P., Weiden, P. J., & Walling, D. P. (2016). Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s116029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.